Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality

OBJECTIVES: The current demographic information from China reports that 10%-19% of patients hospitalized with coronavirus disease (COVID-19) were diabetic. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are considered first-line agents in patients with d...

Descripción completa

Detalles Bibliográficos
Autores principales: Stafford, Emma G., Riviere, Jim E., Xu, Xuan, Kawakami, Jessica, Wyckoff, Gerald J., Jaberi-Douraki, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Pharmacists Association®. Published by Elsevier Inc. 2020
Materias:
Science and Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262497/
https://www.ncbi.nlm.nih.gov/pubmed/32561317
http://dx.doi.org/10.1016/j.japh.2020.05.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262497/
https://www.ncbi.nlm.nih.gov/pubmed/32561317
http://dx.doi.org/10.1016/j.japh.2020.05.018

Ejemplares similares